TRADES
Latest Trades
128
results found
FUND
DATE
ACTION
TICKER
COMPANY
SHARES
% of ETF
ARKG 26 Sep 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 404,329 0.0481
ARKK 26 Sep 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 1,025,559 0.0388
ARKG 23 Sep 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 2,921,978 0.3349
ARKK 23 Sep 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 171,849 0.0063
ARKG 22 Sep 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 1,640,566 0.1871
ARKK 22 Sep 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 395,301 0.0143
ARKG 21 Sep 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 502,223 0.0577
ARKK 21 Sep 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 286,453 0.0107
ARKG 20 Sep 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 555,333 0.0636
ARKK 20 Sep 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 291,614 0.0108
ARKG 19 Sep 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 588,745 0.0647
ARKK 19 Sep 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 398,769 0.0144
ARKG 16 Sep 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 427,871 0.0445
ARKK 16 Sep 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 1,256,764 0.0432
ARKG 14 Sep 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 129,205 0.0140
ARKK 14 Sep 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 199,695 0.0070
ARKG 13 Sep 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 79,472 0.0082
ARKK 13 Sep 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 127,884 0.0042
ARKG 6 Sep 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 184,163 0.0172
ARKK 6 Sep 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 276,796 0.0086
ARKG 2 Sep 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 273,400 0.0268
ARKK 2 Sep 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 796,075 0.0260
ARKG 1 Sep 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 622,259 0.0612
ARKK 1 Sep 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 1,915,952 0.0626
ARKG 31 Aug 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 11,694 0.0011
ARKK 31 Aug 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 35,842 0.0012
ARKG 30 Aug 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 90,906 0.0089
ARKK 30 Aug 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 276,489 0.0089
ARKG 29 Aug 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 71,429 0.0070
ARKK 29 Aug 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 227,197 0.0073
ARKG 26 Aug 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 488,049 0.0467
ARKK 26 Aug 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 1,493,076 0.0472
ARKG 25 Aug 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 316 0.0000
ARKK 25 Aug 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 923 0.0000
ARKG 23 Aug 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 63,360 0.0063
ARKK 23 Aug 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 190,534 0.0063
ARKG 22 Aug 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 834,142 0.0814
ARKK 22 Aug 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 2,504,760 0.0793
ARKK 19 Aug 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 848,533 0.0288
ARKG 18 Aug 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 132,022 0.0141
ARKK 18 Aug 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 1,006,821 0.0340
ARKK 10 Aug 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 1,068,097 0.0345
ARKG 26 Jul 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 567,281 0.0521
ARKK 26 Jul 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 2,197,526 0.0609
ARKG 25 Jul 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 444,611 0.0419
ARKK 25 Jul 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 1,425,762 0.0407
ARKG 18 Jul 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 136,687 0.0140
ARKK 18 Jul 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 1,023,490 0.0334
ARKG 15 Jul 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 34,974 0.0037
ARKK 15 Jul 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 251,692 0.0085
ARKG 14 Jul 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 69,701 0.0072
ARKK 14 Jul 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 653,843 0.0219
ARKG 12 Jul 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 189,299 0.0196
ARKK 12 Jul 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 1,473,077 0.0478
ARKG 11 Jul 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 84,389 0.0086
ARKK 11 Jul 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 776,091 0.0241
ARKG 5 Jul 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 57,530 0.0060
ARKK 5 Jul 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 264,969 0.0083
ARKG 1 Jul 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 454,816 0.0467
ARKK 30 Jun 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 1,543,230 0.0451
ARKK 29 Jun 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 1,574,932 0.0459
ARKG 20 May 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 487,451 0.0461
ARKK 20 May 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 1,751,455 0.0499
ARKG 19 May 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 1,104 0.0001
ARKK 19 May 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 3,986 0.0001
ARKG 18 May 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 1,054,814 0.1031
ARKK 18 May 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 3,680,566 0.1061
ARKG 17 May 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 944,210 0.0944
ARKK 17 May 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 3,105,693 0.0920
ARKG 26 Apr 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 292,442 0.0351
ARKK 26 Apr 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 1,017,209 0.0377
ARKG 25 Apr 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 52,035 0.0064
ARKK 25 Apr 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 180,527 0.0069
ARKG 22 Apr 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 1,300,840 0.1515
ARKG 20 Apr 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 357,872 0.0402
ARKK 20 Apr 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 523,281 0.0176
ARKG 19 Apr 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 68 0.0000
ARKK 19 Apr 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 123 0.0000
ARKG 18 Apr 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 31,528 0.0034
ARKK 18 Apr 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 602,754 0.0200
ARKG 14 Apr 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 173,826 0.0195
ARKK 14 Apr 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 619,872 0.0214
ARKG 13 Apr 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 361,847 0.0405
ARKK 13 Apr 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 1,190,284 0.0419
ARKK 31 Mar 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 3,850,111 0.1247
ARKK 10 Feb 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 2,179,659 0.1017
ARKK 27 Jan 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 989,771 0.0390
ARKG 26 Jan 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 350,980 0.0447
ARKK 26 Jan 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 895,395 0.0361
ARKG 25 Jan 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 138,954 0.0176
ARKK 25 Jan 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 828,483 0.0313
ARKG 24 Jan 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 313,045 0.0366
ARKK 24 Jan 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 650,644 0.0252
ARKK 21 Jan 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 597,200 0.0238
ARKG 20 Jan 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 411,596 0.0552
ARKG 12 Jan 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 242,472 0.0360
ARKG 10 Jan 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 50,000 0.0069
ARKK 10 Jan 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 269,581 0.0122
ARKK 7 Jan 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 741,015 0.0355
ARKG 6 Jan 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 698,931 0.1008
Latest Blogs
ARK by Cathie Wood is still suffering a year after its apex.

Cathie Wood's flagship exchange-traded fund hit an all-time high in February of this year. Her preferred disruptive-tech chasing strategy may still be in for a lot of suffering after a year and a 53 percent fall.

After a dramatic decline last month, the ARK Innovation ETF (ticker: ARKK) has steadied off - it's practically flat in February – but the headwinds surrounding its speculative growth picks are just becoming more vital. Many businesses that thrived during the pandemic are being hammered by the economic reopening, not only because yields are rising as investors prepare for the US Federal Reserve to raise interest rates, which is terrible news for unprofitable businesses, but also because the economic reopening is hammering many of the businesses that thrived during the pandemic.

Roku, Teladoc, and Zoom, all winners in the work-from-home era, have had their stock prices plummet by as much as 74% in the past year.

Short bets against ARK, according to IHS Markit data, hit a fresh high of 11.4 percent of outstanding shares this week. The Tuttle Capital Short Innovation ETF (SARK), which beats the ARK, now has assets worth more than $US300 million ($416 million).

"Those equities are supported by speculation, and speculation pays less well when the Fed raises rates," said Brent Schutte, chief investment strategist at Northwestern Mutual Wealth Management Co. "Much of what's happening in the market reminds me of what happened in the late 1990s when market segments were bid up to levels based on future assumptions."

Because its price chart resembles that of the Nasdaq index of technology businesses from more than two decades ago, analogies to that period and the dot-com implosion that followed are becoming more common in discussions of ARK.

"Today marks the 253rd trading day from ARK's all-time high," Jessica Rabe, co-founder of DataTrek Research, wrote in a Tuesday note, "while the Nasdaq was down 60% from its dot-com bubble top on the same day in 2001."

"If 2000/2001 analog holds, we should see ARK continuing to fall over the following three weeks. The Nasdaq dropped 18.7% in the next 16 trading days "recent."

Net flows are positive.

The better news for investors and Ms. Wood is that there may be some immediate respite. The Nasdaq rose 41% in six weeks in 2001 before falling.

The ARK Investment Management did not respond to a request for comment.

Most of ARK's $US15 billion asset loss has been attributed to bad performance, a plus for the company. Since the fund achieved an intraday high of $US159.70 a year ago this week, investors have withdrawn only around $US465 million, and ARK's net flows this year are positive despite a more than 20% drop.

This exceptional loyalty prevents a worsening situation and allows Wood's approach to recovering. The star fund manager has consistently emphasized that her funds have a five-year investment horizon and that she believes in many good options.

Mr. Schutte, on the other hand, says the drop is understandable because several of the company's biggest bets, such as Teladoc and Zoom, are becoming less significant as COVID-19 approaches.

"During the pandemic, there were a lot of questions about what would happen to society and how we'd go about our lives," he added.

"You drew in new investors who wanted to know "what are the upcoming themes I should invest in?" I believe you got a washout of it as well."

On Friday, Cathie Wood sold $148.9 million worth of Palantir stock, halving her exposure.

Ark Investment Management, run by Cathie Wood, sold more Palantir Technologies Inc PLTR -6.39 percent shares on Friday, cutting its stake in the Peter Thiel-backed company.

According to Friday's closing price, the famous investment management firm sold 13.5 million shares of the big data company, valued at $148.9 million.

Palantir's stock fell 6.4 percent to $11.02 per share on Friday. The stock has lost 16% of its value in the last week.

Before Friday's trade, Ark Invest held 25.53 million shares in Palantir, suggesting that the famous stock picker had trimmed over 52 percent of its total keeping a day later.

After the business disclosed lower-than-expected fourth-quarter earnings before the market opened on Thursday, Ark Invest, located in St. Petersburg, California, dumped shares in Palantir for the second time.

The software firm, well-known for its work with government organizations, posted earnings of 2 cents per share, falling short of the analyst consensus of 4 cents. The company recorded quarterly revenues of $432.87 million, higher than the $417.69 million predicted by analysts.

Palantir's stock had been sold for 4.77 million shares by the investment firm the day before.

All six of Ark Invest's active exchange-traded funds own Palantir stock, including the flagship Ark Innovation ETF ARKK -4.88 percent.

Before the recent sell-off, Ark Invest had been stockpiling Palantir shares for months.

Cathie Wood appeared on television to defend her ARK funds' dismal performance. It didn't go quite as planned.

The Ark Innovation ETF (ARKK), Cathie Wood's flagship fund, is down 30% year to date and more volatile than almost any other fund on the market. On CNBC's Halftime Report, Wood jumped at the chance to defend the fund and its deflated price, which is currently $68.80, down from $155 a year ago.

"We've seen a significant decline," Wood said, adding, "We feel innovation is at bargain basement zone." Even though her ETF was underperforming, she emphasized that her companies were still "very inexpensive" and that the current fund loss was temporary. When the call's 40 free minutes were finished, Zoom gave her an extra 10 minutes to complete the interview.

Having Zoom check to see whether she was "running out of time?" Wood, who has been aggressively buying up shares in Zoom and other IT firms that have fallen from their pandemic highs, was unhappy. Zoom, like Wood's other significant tech holdings, Teladoc Health, Roku, and Roblox, is down 20% to 40% year to date as investors worry about rising interest and inflation rates.

However, a significant chunk of the interview was devoted to a personal assault on Cathie Wood, who was named the most excellent stock picker in 2020 by Bloomberg's then-Editor-in-Chief Matthew Winkler after correctly forecasting that Tesla will one day be valued at more than $1 trillion.

Wood bluntly ignored Tuttle Capital Management's Short Innovation ETF (SARK), which tracks the inverse performance of ARKK using swaps contracts for the sole purpose of betting against Cathie Wood's selections. "They're not conducting any research." She explained, "All they're doing is shorting innovation."

Of course, SARK is betting against Cathie Woods, not on innovation. "Well, we stand for invention," Wood responded. The SARK ETF has gained 55 percent since its debut, whereas the ARKK ETF has declined by 42 percent.

Tuttle Capital Management CEO Matthew Tuttle chimed in on the SARK ETF, calling it a "tool" for investors. According to SARK, "to convey a negative view of the market, innovative enterprises, the current rising rate environment, or a [specific] portfolio manager if they wish." "It's un-American not to have options in the marketplace," Tuttle told Insider on Thursday.

In any event, Wood is making progress. Her main concern currently is bearish calls on her ETF. "Our major concern is that our investors convert temporary losses into long-term losses," Wood continued.